AT1 receptor blockers by ARBs induce a dose-dependent blockade of angiotensin II-induced effects, resulting in a reduction in BP, cardiac and vascular hypertrophy, proteinuria and glomerular sclerosis21,22. This evidence concerns the gene AGTR1 and vascular smooth muscle hypertrophy.